Replies to post #76196 on Avid Bioservices Inc (CDMO)

[geocappy1]

So with regard to Bavi/RIB we know it is not a quick home run to replace interferon in a 12 week trial against the SOC as we had hoped it to be.

So now the question are

1) Could Bavi/Rib replace rib/interferon in a longer dosing trial?
2) Could Bavi alone with other drugs (Pharmasset/Gilead) or
(Incivek/Telepravir or Bocepravir) outperform the combo with
RIB/Interferon?

The results of the Pharmasset/Gilead may just bring Bavi back in the picture as a potential partner. SK has stated we need to partner with someone who is vested in HepC trials as their main business. I would think Pharmasset/Gilead should be looking around to find another drug such as Bavi.